Twist Bioscience (NASDAQ:TWST) Releases Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Twist Bioscience (NASDAQ:TWST - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10), Zacks reports. The company had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience updated its Q3 2025 guidance to EPS and its FY 2025 guidance to EPS.

Twist Bioscience Price Performance

TWST stock traded down $1.79 during trading on Friday, hitting $30.82. 1,158,651 shares of the stock traded hands, compared to its average volume of 968,775. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -9.12 and a beta of 2.54. Twist Bioscience has a one year low of $30.72 and a one year high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company has a 50 day simple moving average of $38.63 and a 200 day simple moving average of $43.65.

Insider Transactions at Twist Bioscience

In related news, CEO Emily M. Leproust sold 5,042 shares of the firm's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $189,831.30. Following the completion of the sale, the chief executive officer now directly owns 655,432 shares of the company's stock, valued at $24,677,014.80. This trade represents a 0.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dennis Cho sold 689 shares of the business's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $25,940.85. Following the completion of the transaction, the insider now directly owns 110,849 shares in the company, valued at approximately $4,173,464.85. This represents a 0.62 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,991 shares of company stock valued at $742,654. Corporate insiders own 3.01% of the company's stock.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of research analyst reports. Guggenheim reaffirmed a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday. Robert W. Baird reduced their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday. Barclays decreased their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. JPMorgan Chase & Co. cut their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Tuesday. Finally, Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.